Ana Sayfa Ana Sayfa Halen geliştirilmekte olan potansiyel COVID-19 terapötikleri

Halen geliştirilmekte olan potansiyel COVID-19 terapötikleri

Aşağıdaki Tabloda  , yoğunlaşılmış ilaç geliştirme yaşam döngüsünün farklı aşamalarındaki diğer birçok adayı özetlemektedir. John Cahill

Company/research Drug/vaccine candidate Development stage
MIGAL Infectious Bronchitis Virus (IBV) vaccine Pre-clinical trials
APEIRON Biologics APN01 Phase I
Tonix Pharmaceuticals TNX-1800 Initial evaluation
Innovation Pharmaceuticals Brilacidin Initial evaluation
Clover Biopharmaceuticals S-Trimer vaccine Pre-clinical trials
Vaxart TBC Pre-clinical trials
CytoDyn Leronlimab Phase II for HIV and fast tracked for COVID-19
Applied DNA Sciences and Takis Biotech Linear DNA Vaccine Pre-clinical trials
Novavax MERS coronavirus vaccine Phase I in 2020
Biocryst Pharma Galidesivir Advanced animal testing
Takeda H-IG therapy TBC
Heat Biologics gp96 vaccine Early development
Pfizer and BioNTech mRNA vaccine, BNT162 Clinical programme development with Fosun in China
Generex Ii-Key immune system activation Clinical programme development in China
Vir Biotechnology/Wuxi

Vir Biotechnology/Alnylam

MABs binding to virus

siRNA candidates

Janssen Pharmaceuticals PREZCOBIX® HIV medication (darunavir/cobicistat) TBC

As evident above, drug discovery and clinical research activities in COVID-19 prevention and treatment is increasing in pace; it would not be surprising if a workable vaccine has already been discovered and is being tested at present. However, it will take some time to establish the complete safety and efficacy of the successful candidates. Despite this, with the combined knowledge and current urgency that now exists in R&D, we should have reason to be confident of a future without COVID-19. In the meantime, although unfortunately this may still be some months away, we must follow national health authority guidance, trust in science and stay safe for each other.